Cipmolnu (Molnupiravir 200 Mg Capsules) | Lagevrio Alternative | Treats Mild to Moderate COVID-19 in High-Risk Adults
Cipmolnu 200 Mg Capsule is an oral antiviral medication for treating mild to moderate COVID-19 in adults. It reduces viral load and prevents virus replication. Developed initially for the flu, it requires careful use, especially in patients over 60 or with chronic conditions, and should be taken for five consecutive days.
Product Overview
Cipmolnu Capsules is a specialized antiviral therapy containing Molnupiravir (200 mg). Cipmolnu Capsules is a nucleoside analogue specifically developed for the oral treatment of mild-to-moderate COVID-19 in adult patients. By introducing genomic errors during the viral replication process, it prevents the virus from spreading and reduces the risk of disease progression to more severe stages.
Product Composition
- Active Ingredient: Molnupiravir
- Pharmacological Class: Nucleoside Analogue / Antiviral
- Strength: 200 mg per capsule
- Formulation: Hard gelatin capsules
- Excipients: May include microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate
Product Specifications
| Feature | Specification |
| Drug Category | Direct-Acting Antiviral |
| Therapeutic Class | RNA Polymerase Inhibitor |
| Metabolism | Hydrolyzed to active form (NHC) |
| Onset of Action | Rapid systemic absorption |
| Storage | Store below 30°C in a dry place |
Mechanism of Action
- Viral Error Catastrophe: Molnupiravir works through a process known as lethal mutagenesis. Once inside the body, it is converted into its active form, which resembles a natural building block of viral RNA.
- Polymerase Substrate: The viral enzyme responsible for copying the genetic code (RNA-dependent RNA polymerase) mistakenly incorporates the drug into the new viral RNA strands.
- Mutation Accumulation: Because the drug can mimic multiple genetic "letters," it causes the virus to make frequent copying errors.
- Inhibition of Replication: These cumulative errors eventually become so widespread that the virus can no longer produce functional copies of itself, a state termed error catastrophe, which effectively lowers the viral load in the body.
Key Benefits
- Oral Convenience: Unlike many other COVID-19 treatments that require intravenous administration, Cipmolnu is taken as a simple capsule, allowing for home-based treatment.
- Reduced Hospitalization Risk: Clinically shown to significantly lower the risk of hospitalization and death in high-risk patients when initiated early.
- Broad-Spectrum Potential: Due to its mechanism of targeting highly conserved viral replication processes, it maintains efficacy against various variants of concern.
- Early Intervention Tool: Designed to be used immediately following a positive diagnosis, helping to manage symptoms before they become critical.
- High Resistance Threshold: The process of "error catastrophe" makes it difficult for the virus to develop resistance compared to treatments that target specific surface proteins.
Precautions
Medical supervision
- Use Cipmolnu (Molnupiravir 200 mg Capsules) only under proper medical supervision
- Do not self-medicate or change dose without advice
- Start treatment as early as possible after diagnosis
- Complete the full prescribed course
Pregnancy and breastfeeding
- Not recommended during pregnancy unless clearly advised by a doctor
- Effective contraception should be used during treatment
- Breastfeeding should be avoided during and shortly after therapy (as advised)
Health conditions
| Condition | Precaution |
|---|---|
| Liver disease | Use with caution and monitoring |
| Kidney disease | Usually no adjustment needed, but medical advice required |
| Weak immunity | Requires close monitoring |
| Severe COVID-19 | Not suitable for severe or hospitalized cases |
Reproductive safety
- May affect fetal development in animal studies
- Men and women of reproductive age should use reliable contraception
- Continue contraception for a period after completing treatment (as advised)
General safety
- Not a substitute for vaccination
- Do not use for prevention unless prescribed
- Avoid sharing medicine with others
Monitoring advice
- Watch for worsening symptoms like breathing difficulty or chest pain
- Seek immediate medical help if condition worsens
- Follow isolation and COVID-19 safety guidelines during treatment
Lifestyle precautions
- Stay hydrated and rest adequately
- Avoid alcohol if feeling weak or unwell
- Follow doctor’s instructions strictly for best results
Usage
Cipmolnu is a time-sensitive antiviral treatment. For the medication to effectively induce "error catastrophe" in the virus, it must be administered as soon as possible after symptoms appear.
Dosage and Administration
Adhering to the full clinical course is essential to ensure the viral load is successfully suppressed and to prevent the development of viral resistance.
Treatment Window: Therapy must be initiated within 5 days of the onset of symptoms for maximum efficacy.
Administration: The capsules must be swallowed whole with plenty of water. They can be taken with or without food.
Course Completion: The full 5-day course must be finished even if the patient begins to feel better. Stopping early may allow the virus to continue replicating.
Contraception Requirements:
Females of Childbearing Potential: Should use a reliable method of birth control during treatment and for 4 days after the final dose.
Males with Partners of Childbearing Potential: Should use a reliable method of contraception during treatment and for at least 3 months after the final dose, as the drug may affect sperm.
Pregnancy and Breastfeeding: This medication is not recommended during pregnancy or breastfeeding due to potential risks to the developing fetus or infant.
Age Restriction: It is generally not authorized for use in patients under 18 years of age because it may affect bone and cartilage growth.
Missed Dose: If a dose is missed within 10 hours of the scheduled time, take it immediately. If more than 10 hours have passed, skip the missed dose and take the next one at the regular time. Do not take a double dose.
Uses
Cipmolnu is indicated for the treatment of specific viral infections in adults who are at a higher risk of developing severe illness.
Primary Therapeutic Uses
Treatment of Mild-to-Moderate COVID-19: Specifically indicated for adults who have tested positive for SARS-CoV-2 and are experiencing early-stage symptoms.
Prevention of Disease Progression: Targeted at patients with at least one risk factor for severe illness (such as obesity, older age, diabetes, or heart disease) to prevent the need for hospitalization.
Management of Viral Load: Effectively reduces the amount of active virus in the body, which can help in reducing the duration of the illness.
Alternative for High-Risk Individuals: Provides a critical oral treatment option for patients who cannot access or are not eligible for other authorized COVID-19 therapies.
Variant Management: Utilized to treat infections caused by various strains of the virus, as its mechanism of action remains effective against most circulating mutations.
Side effects
Common side effects
- Diarrhea
- Nausea
- Headache
- Dizziness
- Fatigue
- Vomiting
Digestive system effects
- Stomach discomfort
- Abdominal pain
- Loss of appetite
- Mild indigestion
General effects
- Weakness
- Body ache
- Feeling unwell
- Mild fever (in some cases)
Skin reactions
- Rash (rare)
- Itching (rare)
Serious side effects (rare)
| Serious effect | Possible signs |
|---|---|
| Severe allergic reaction | Swelling, rash, breathing difficulty |
| Liver issues (rare) | Yellow skin, dark urine, fatigue |
| Worsening infection | Increased breathlessness, chest pain, high fever |
Important warning
- Stop use and seek immediate medical attention if serious symptoms occur
- Do not use as a substitute for vaccination or emergency care
- Monitor symptoms closely during COVID-19 infection and follow medical advice strictly
FAQs
Q: What is Cipmolnu used for?
A: Cipmolnu is used to treat mild to moderate COVID-19 in adults who have a high risk of disease progression, including hospitalisation or death. It is used in patients with an oxygen saturation (SpO2) greater than 93% who are not hospitalised at the time of treatment initiation.
Q: How does Cipmolnu work?
A: Molnupiravir is a prodrug that is converted in the body to an active antiviral compound. It works by incorporating itself into the RNA of the COVID-19 virus, causing an accumulation of errors in the viral genome known as viral error catastrophe. This stops the virus from multiplying and reduces viral load and disease severity.
Q: When should Cipmolnu be started?
A: Cipmolnu should be started within 5 days of the onset of COVID-19 symptoms. It is most effective when initiated early in the course of the illness.
Q: What are the common side effects of Cipmolnu?
A: Common side effects include nausea, vomiting, diarrhoea, dizziness, and headache. Most are mild and resolve on their own. Consult your doctor if they persist or worsen.
Q: Who should not take Cipmolnu?
A: Cipmolnu should not be taken by patients who are allergic to Molnupiravir, children and adolescents below 18 years of age, pregnant women, or patients requiring immediate hospitalisation due to severe COVID-19. It should not be used for more than 5 consecutive days or for prevention of COVID-19.
Q: Can Cipmolnu be used during pregnancy?
A: No, Cipmolnu is contraindicated during pregnancy as Molnupiravir may cause harm to the developing baby. Women of childbearing potential should use reliable contraception during treatment and for 4 days after the last dose.
Q: Is Cipmolnu safe during breastfeeding?
A: Cipmolnu is not recommended during breastfeeding. Consult your doctor before taking this medicine while breastfeeding.
Q: Can Cipmolnu be used in children?
A: No, Cipmolnu is not recommended for children and adolescents below 18 years of age. It is only authorised for use in adults.
Q: Can Cipmolnu be used in patients with severe COVID-19?
A: No, Cipmolnu is not indicated for patients with severe COVID-19 requiring hospitalisation. Clinical trials have shown that patients hospitalised with severe COVID-19 have not benefited from Molnupiravir treatment.
Q: Can Cipmolnu be used to prevent COVID-19?
A: No, Cipmolnu is not approved or authorised for the prevention of COVID-19. It is only for the treatment of mild to moderate COVID-19 in high-risk adults.
Q: Can Cipmolnu be used in patients with kidney or liver disease?
A: Inform your doctor if you have kidney or liver problems before taking Cipmolnu. Drink plenty of water during treatment to prevent dehydration and kidney damage.
Interactions
Other medicines
- No major clinically significant drug interactions have been widely reported
- Still, inform your doctor about all ongoing medicines before starting treatment
Antiviral medicines
- Avoid combining with other COVID-19 antivirals unless prescribed
- Combined use should only be under specialist supervision
Immunosuppressants
- Patients on immune-suppressing therapy should use only under close medical monitoring
- Infection progression may differ in such cases
Hormonal medicines (including contraceptives)
- No direct interaction confirmed, but medical advice is recommended
- Use reliable contraception during treatment as advised
Antibiotics and supportive medicines
- May be used together if prescribed for secondary infections
- No known major interaction, but monitoring is advised
General advice
- Always inform your healthcare provider about all prescription, OTC, and herbal medicines
- Avoid self-medication during COVID-19 treatment
- Follow prescribed dose and duration strictly for best results
| Manufacturer | : | Cipla Pharma, India |
| Trade Name | : | Lagevrio |
| Generic Search | : | Molnupiravir |
| Strength | : | 200mg |
Latest Products
